This study was simultaneously presented at TCT and published at JACCE, and it aims at showing the one-year outcomes of this new TAVR device, though follow-up is at 5 years.
Primary end point was all cause mortality and secondary end points included clinical and echocardiographic events.
With a total 941 patients (82,4 ± 5,9 years, 65,7% women, STS 5,8%) from Europe, Australia and Canada, researchers observed 12.1% mortality rate, 6.6% cardiovascular mortality, 2.2% stroke and 2.5% acute myocardial infarction.
Mean transvalvular gradient and valve area resulted 8.6 mmHg and 1.75 cm², respectively.
Read also: TCT 2018 | NEOPRO: A Registry for Acurate neo and Evolut PRO.
Moderate to severe paravalvular leak was 2.6% and pacemaker rate at one year was 21.3%. All patients improved functional class and quality of life.
Original title: One-Year Outcomes with a Self-Expanding, Repositionable Transcatheter Heart Valve in Severe Aortic Stenosis Patients: PORTICO-I.
Presenter: Lars Sondergaard.
Get the latest scientific articles on interventional cardiologySubscribe to our weekly newsletter
We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.
